All News


All series


All All News

Survivors with children face some of the biggest challenges when it comes to visualizing the future. After my breast cancer diagnosis in 1986, it was my daughter's future, rather than my own, for which I bargained.

In topline findings from the phase 3 TITAN trial (NCT02489318) announced today by Janssen, Erleada (apalutamide) in combination with androgen deprivation therapy (ADT) significantly improved radiographic progression-free survival (rPFS) and overall survival (OS) versus placebo in patients with metastatic castration-sensitive prostate cancer.